aTyr Pharma Inc (NASDAQ:LIFE) – Research analysts at William Blair issued their Q1 2019 earnings per share (EPS) estimates for aTyr Pharma in a research note issued to investors on Monday. William Blair analyst Y. Xu expects that the biotechnology company will earn ($0.37) per share for the quarter. William Blair also issued estimates for aTyr Pharma’s Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.40) EPS and Q4 2019 earnings at ($0.42) EPS.
A number of other brokerages have also recently commented on LIFE. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, JPMorgan Chase & Co. downgraded aTyr Pharma from a “neutral” rating to an “underweight” rating in a report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. aTyr Pharma has a consensus rating of “Hold” and a consensus target price of $4.75.
Hedge funds have recently bought and sold shares of the company. Deutsche Bank AG purchased a new position in shares of aTyr Pharma in the fourth quarter worth $199,000. Dimensional Fund Advisors LP raised its stake in shares of aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 25,676 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of aTyr Pharma in the third quarter worth $455,000. Renaissance Technologies LLC increased its position in aTyr Pharma by 143.2% during the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after acquiring an additional 164,500 shares during the last quarter. Finally, Artal Group S.A. increased its position in aTyr Pharma by 100.0% during the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $1,750,000 after acquiring an additional 250,000 shares during the last quarter. Hedge funds and other institutional investors own 58.65% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.